drugset / Trial / NCT05370521
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
RandomizedParallel-groupTriple-blindTreatment
Summary
An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens
Timeline
- Start
- 2022-05-15
- Primary completion
- 2023-08-03
- Completion
- 2023-08-31
Outcome
Outcome not reported
Stopped: “The study was discontinued early by the sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tildacerfont | Small molecule | 50 mg | Oral |
| Subject | Tildacerfont | Small molecule | 100 mg | Oral |
| Subject | Tildacerfont | Small molecule | 200 mg | Oral |